Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study to Determine Safety and Tolerability of MG-S-2525 and to Evaluate Its Pharmacokinetic Profile in Healthy Volunteers

Trial Profile

A Phase I Study to Determine Safety and Tolerability of MG-S-2525 and to Evaluate Its Pharmacokinetic Profile in Healthy Volunteers

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Nov 2018

At a glance

  • Drugs MG-S-2525 (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Metagone Biotech
  • Most Recent Events

    • 16 Nov 2018 According to a Metagone Biotech media release, the IND application has been approved by the TFDA and the company will begin recruitment in this study in Dec 2018, at the Tri-Service Hospital in Taipei, Taiwan. The entire study is anticipated to be completed by end of Q2 2019.
    • 05 Sep 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top